SAB4700623
Monoclonal Anti-CD24 antibody produced in mouse
clone SN3, purified immunoglobulin, buffered aqueous solution
Synonyme(s) :
Anti-CD24
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352203
Nomenclature NACRES :
NA.41
Produits recommandés
Source biologique
mouse
Conjugué
unconjugated
Forme d'anticorps
purified immunoglobulin
Type de produit anticorps
primary antibodies
Clone
SN3, monoclonal
Forme
buffered aqueous solution
Espèces réactives
human
Concentration
1 mg/mL
Technique(s)
flow cytometry: suitable
Isotype
IgG1
Numéro d'accès NCBI
Numéro d'accès UniProt
Conditions d'expédition
wet ice
Température de stockage
2-8°C
Modification post-traductionnelle de la cible
unmodified
Informations sur le gène
human ... CD24(100133941)
Description générale
The antibody SN3 reacts with CD24, a 35-45 kDa heavily glycosylated cell surface antigen. CD24 is expressed by granulocytes, B lymphocytes and by some activated T cells and T cell malignancies. It is not expressed on human thymocytes.
Immunogène
Glycoproteins purified from human NALM-1 cell line
Application
The reagent is designed for Flow Cytometry analysis. Suggested working dilution for Flow Cytometry is 2-8 μg/mL of sample. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the investigator.
Caractéristiques et avantages
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Forme physique
Solution in phosphate buffered saline, pH 7.4, with 15 mM sodium azide.
Clause de non-responsabilité
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Code de la classe de stockage
10 - Combustible liquids
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Athanassios Vassilopoulos et al.
The Journal of biological chemistry, 289(35), 24202-24214 (2014-07-10)
Drug resistance and cancer metastasis are two major problems in cancer research. During a course of therapeutic treatment in Brca1-associated tumors, we found that breast cancer stem cells (CSCs) exhibit an intrinsic ability to metastasize and acquire drug resistance through
Thomas Hofner et al.
Urologic oncology, 32(5), 678-686 (2014-03-19)
To evaluate CD24/CD44/CD47 cancer stem cell marker expressions in bladder cancer (BCa) and provide data on their prognostic significance for clinical outcome in patients undergoing radical cystectomy (RC). Primary BCa tissue was used for xenograft studies. A tissue microarray was
Martine Croset et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 29(8), 1886-1899 (2014-03-13)
The transcription factor TWIST1 induces epithelial-mesenchymal transition and/or escape to the oncogenic-induced failsafe program, facilitating the intravasation of breast cancer cells in the systemic circulation and their dissemination to the lungs. Its involvement in breast cancer bone metastasis is unknown.
Ying Zhong et al.
Medical oncology (Northwood, London, England), 31(3), 864-864 (2014-02-13)
Breast cancer stem cells are thought to be associated with metastasis and poor prognosis, but their clinical importance remains poorly understood. The aim of this study was to investigate whether certain phenotypes of breast cancer stem cells were clinically important
Chelsea M Black et al.
Cancer immunology research, 2(4), 307-319 (2014-04-26)
A major barrier to vaccines in cancer treatment is their failure to activate and maintain a complete cancer-specific CD8(+) effector T-cell repertoire. Low-avidity T cells are more likely to escape clonal deletion in the thymus when compared with high-avidity T
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique